Pfizer Inc. (PFE) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 8/100
- 10Y CAGR
- 2.5%
- Median YoY
- 0.8%
- YoY volatility
- σ 37.9pp· choppy
- Quarters ≥ 20%
- 8 of 40
- Negative quarters
- 19
- Valuation vs own 10Y history
- P/S 2.5x · 10Y median 3.6x · 30th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 8 of 40 → 8 of 40 pts
- Steadiness (typical swing 37.9pp) → 0 of 25 pts
- Pace (median 0.8% YoY) → 0 of 20 pts
- Latest quarter (2.6% YoY) → 0 of 15 pts
- Score: 8 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 2.5% | 0.8% | 37.9pp | 8 of 40 | 19 |
| EPSEPS | 2% | 21.6% | 2132.2pp | 16 of 32 | 12 |
| Op cash flowOperating cash flow | -2.1% | 4.6% | 87.1pp | 14 of 38 | 18 |
| EBITDAEBITDA | 1% | 3.3% | 282.4pp | 11 of 39 | 17 |
| FCFFree cash flow | -3.5% | 11.5% | 138.1pp | 17 of 38 | 17 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: PFE on the compounders surface · All compounders, ranked